Diabetes drug trial aims to curb dangerous weight gain in HIV patients
NCT ID NCT07336797
Summary
This study is testing if a drug called empagliflozin, commonly used for diabetes, can help control weight gain and related metabolic problems in people living with HIV. It will involve 66 adults with HIV who are overweight and on a specific antiviral treatment known to cause weight gain. Participants will take either empagliflozin or a placebo for six months to see if the drug improves weight, cholesterol, blood sugar, and other health markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Faculty of Pharmacy, Cairo University | Kasr El-Aini, Cairo
RECRUITINGCairo, 11562, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.